Evidence map›Paper›PMID 19010858›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2008

Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.

H Charles Manning, Nipun B Merchant, A Coe Foutch, John M Virostko, Shelby K Wyatt, Chirayu Shah, Eliot T McKinley, Jingping Xie, Nathan J Mutic, M Kay Washington and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. [Comparison of early response to combined chemotherapy gemcitabine-cisplatin in non-small cell lung cancer animal model between usingSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2017
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. High-yielding, automated production of 3'-deoxy-3'-[(18)F]fluorothymidine using a modified Bioscan Coincidence FDG reaction module.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2015
    Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

H Charles ManningVanderbilt Institute of Imaging Science, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA.
Nipun B Merchant
A Coe Foutch
John M Virostko
Shelby K Wyatt
Chirayu Shah
Eliot T McKinley
Jingping Xie
Nathan J Mutic
M Kay Washington
Bonnie LaFleur
Mohammed Noor Tantawy
Todd E Peterson
M Sib Ansari
Ronald M Baldwin
Mace L Rothenberg
Darryl J Bornhop
John C Gore
Robert J Coffey
Vanderbilt University Medical Center · USVanderbilt University · USCancer Research And Biostatistics · US

Funding

Understanding and Controlling p120 Dysfunction in CRCP50CA095103 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COFFEY, ROBERT J. · 2002 to 2017
$33.6M
TRANSFORMING GROWTH FACTORS IN COLONIC NEOPLASIAR01CA046413 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COFFEY, ROBERT J. · 1988 to 2016
$8.8M
Prevention &Metastasis: Final Frontiers in Colon CancerU01CA084239 · NCI · VANDERBILT UNIVERSITY · PI COFFEY, ROBERT J. · 1999 to 2009
$8.0M
Postdoctoral Training in Biomedical MRI and MRST32EB001628 · NIBIB · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John C Gore · 2003 to 2026
$7.0M
South-Eastern Center for Imaging Animal Models of CancerU24CA126588 · NCI · VANDERBILT UNIVERSITY · PI GORE, JOHN C · 2007 to 2011
$2.1M
Biological Basis of Imaging Biomarkers in Colorectal CancerR01CA140628 · NCI · VANDERBILT UNIVERSITY · PI MANNING, HENRY CHARLES · 2009 to 2013
$1.5M
Predoctoral Training Program in Biomedical ImagingT32EB003817 · NIBIB · VANDERBILT UNIVERSITY · PI GORE, JOHN C · 2004 to 2008
$1.3M
INTEGRATED ASSESSMENT OF NOVEL THERAPIES IN ONCOLOGYK24CA082301 · NCI · VANDERBILT UNIVERSITY · PI ROTHENBERG, MACE L · 1999 to 2008
$1.1M
Synergizing Quantitative HTS Technologies to Guide MIA Discovery and DevelopmentK25CA127349 · NCI · VANDERBILT UNIVERSITY · PI MANNING, HENRY CHARLES · 2008 to 2012
$709k
Small Animal PET ScannerS10RR017858 · NCRR · VANDERBILT UNIVERSITY · PI KESSLER, ROBERT MICHAEL · 2003 to 2003
$500k
NCI NIH HHS CA 46413NCI NIH HHS K24 CA082301NCI NIH HHS K25 CA127349NCI NIH HHS P50 CA095103NCI NIH HHS R01 CA046413NCI NIH HHS R01 CA140628NCI NIH HHS U01 CA084239NCI NIH HHS U24 CA126588NCRR NIH HHS 1S10 RR17858NCRR NIH HHS S10 RR017858NIBIB NIH HHS T32 EB001628NIBIB NIH HHS T32 EB003817NIBIB NIH HHS T32 EB03817PHS HHS P50 95103PHS HHS U01 084239
6 · The paper itself

Abstract

purposeTo evaluate noninvasive molecular imaging methods as correlative biomarkers of therapeutic efficacy of cetuximab in human colorectal cancer cell line xenografts grown in athymic nude mice. The correlation between molecular imaging and immunohistochemical analysis to quantify epidermal growth factor (EGF) binding, apoptosis, and proliferation was evaluated in treated and untreated tumor-bearing cohorts. EXPERIMENTAL

designOptical imaging probes targeting EGF receptor (EGFR) expression (NIR800-EGF) and apoptosis (NIR700-Annexin V) were synthesized and evaluated in vitro and in vivo. Proliferation was assessed by 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) positron emission tomography. Assessment of inhibition of EGFR signaling by cetuximab was accomplished by concomitant imaging of NIR800-EGF, NIR700-Annexin V, and [18F]FLT in cetuximab-sensitive (DiFi) and insensitive (HCT-116) human colorectal cancer cell line xenografts. Imaging results were validated by measurement of tumor size and immunohistochemical analysis of total and phosphorylated EGFR, caspase-3, and Ki-67 immediately following in vivo imaging.

resultsNIR800-EGF accumulation in tumors reflected relative EGFR expression and EGFR occupancy by cetuximab. NIR700-Annexin V accumulation correlated with cetuximab-induced apoptosis as assessed by immunohistochemical staining of caspase-3. No significant difference in tumor proliferation was noted between treated and untreated animals by [18F]FLT positron emission tomography or Ki-67 immunohistochemistry.

conclusionsMolecular imaging can accurately assess EGF binding, proliferation, and apoptosis in human colorectal cancer xenografts. These imaging approaches may prove useful for serial, noninvasive monitoring of the biological effects of EGFR inhibition in preclinical studies. It is anticipated that these assays can be adapted for clinical use.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabColorectal NeoplasmsDiagnostic ImagingErbB ReceptorsFluorine RadioisotopesHumansImage Interpretation, Computer-AssistedImmunohistochemistryMiceMice, NudePositron-Emission TomographyRadiopharmaceuticalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabErbB ReceptorsFluorine RadioisotopesRadiopharmaceuticalsThymidine

Identifiers

PMID19010858
PMCPMC2657180
OpenAlexW2150085483

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.